SCORPIUS HOLDINGS INC (SCPX)

US42237K4094 - Common Stock

0.4321  -0.07 (-13.3%)

Premarket: 0.415 -0.02 (-3.96%)

Fundamental Rating

2

Overall SCPX gets a fundamental rating of 2 out of 10. We evaluated SCPX against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of SCPX have multiple concerns. SCPX is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SCPX has reported negative net income.
SCPX had a negative operating cash flow in the past year.
SCPX had negative earnings in each of the past 5 years.
In the past 5 years SCPX always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -72.96%, SCPX is not doing good in the industry: 67.75% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -128.83%, SCPX is doing worse than 61.08% of the companies in the same industry.
Industry RankSector Rank
ROA -72.96%
ROE -128.83%
ROIC N/A
ROA(3y)-53.06%
ROA(5y)-51.43%
ROE(3y)-77.93%
ROE(5y)-80.68%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of SCPX (68.54%) is better than 81.98% of its industry peers.
The Profit Margin and Operating Margin are not available for SCPX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

SCPX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SCPX has been increased compared to 1 year ago.
SCPX has more shares outstanding than it did 5 years ago.
SCPX has a worse debt/assets ratio than last year.

2.2 Solvency

SCPX has an Altman-Z score of -9.36. This is a bad value and indicates that SCPX is not financially healthy and even has some risk of bankruptcy.
SCPX has a worse Altman-Z score (-9.36) than 72.97% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that SCPX is not too dependend on debt financing.
The Debt to Equity ratio of SCPX (0.31) is worse than 70.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -9.36
ROIC/WACCN/A
WACC6.31%

2.3 Liquidity

SCPX has a Current Ratio of 0.38. This is a bad value and indicates that SCPX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.38, SCPX is not doing good in the industry: 94.77% of the companies in the same industry are doing better.
SCPX has a Quick Ratio of 0.38. This is a bad value and indicates that SCPX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of SCPX (0.26) is worse than 95.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.26

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.42% over the past year.
SCPX shows a strong growth in Revenue. In the last year, the Revenue has grown by 947.52%.
Measured over the past years, SCPX shows a small growth in Revenue. The Revenue has been growing by 3.85% on average per year.
EPS 1Y (TTM)20.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.01%
Revenue 1Y (TTM)947.52%
Revenue growth 3Y33.35%
Revenue growth 5Y3.85%
Sales Q2Q%356.36%

3.2 Future

Based on estimates for the next years, SCPX will show a very strong growth in Earnings Per Share. The EPS will grow by 41.10% on average per year.
Based on estimates for the next years, SCPX will show a very strong growth in Revenue. The Revenue will grow by 80.70% on average per year.
EPS Next Y97.7%
EPS Next 2Y41.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year63.27%
Revenue Next 2Y80.7%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SCPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SCPX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as SCPX's earnings are expected to grow with 41.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCPX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCORPIUS HOLDINGS INC

NYSEARCA:SCPX (1/7/2025, 8:11:00 PM)

Premarket: 0.415 -0.02 (-3.96%)

0.4321

-0.07 (-13.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-18 2024-11-18
Earnings (Next)N/A N/A
Inst Owners6.65%
Inst Owner ChangeN/A
Ins Owners10.53%
Ins Owner Change0%
Market Cap1.87M
Analysts82.86
Price Target5.1 (1080.28%)
Short Float %3.56%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1052.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-61.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.19
P/FCF N/A
P/OCF N/A
P/B 0.07
P/tB 0.07
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-5.33
FCFYN/A
OCF(TTM)-5.18
OCFYN/A
SpS2.25
BVpS6.61
TBVpS6.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.96%
ROE -128.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.54%
FCFM N/A
ROA(3y)-53.06%
ROA(5y)-51.43%
ROE(3y)-77.93%
ROE(5y)-80.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.24%
Cap/Sales 6.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.26
Altman-Z -9.36
F-Score3
WACC6.31%
ROIC/WACCN/A
Cap/Depr(3y)326.96%
Cap/Depr(5y)240.26%
Cap/Sales(3y)144.6%
Cap/Sales(5y)90.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.01%
EPS Next Y97.7%
EPS Next 2Y41.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)947.52%
Revenue growth 3Y33.35%
Revenue growth 5Y3.85%
Sales Q2Q%356.36%
Revenue Next Year63.27%
Revenue Next 2Y80.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.43%
OCF growth 3YN/A
OCF growth 5YN/A